Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.46 |
| ▸ | AHR | P35869 | 4/20 | 0.43 |
| ▸ | TP53 | P04637 | 1/20 | 0.43 |
| ▸ | PYGL | P06737 | 1/20 | 0.42 |
| ▸ | EPHX1 | P07099 | 2/20 | 0.41 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 3/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
| ▸ | CYP1B1 | Q16678 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | NPC1 | O15118 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.36 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.36 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.36 |
| ▸ | PDE4A | P27815 | 1/20 | 0.36 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL102884 | 0.80 | TRPV4 (0.34) | MAPK1TDP1 | |
| SCHEMBL2096369 | 0.78 | MCL1 (0.38) | MAPK1TDP1ALDH1A1TSHRCYP3A4 | |
| SCHEMBL11092340 | 0.78 | HSD17B10 (0.50) | MAPK1TDP1EPHX1EPHX2ALDH1A1 | |
| SCHEMBL2552386 | 0.78 | SLC2A1 (0.35) | MAPK1TDP1SLC6A2 | |
| SCHEMBL7160560 | 0.78 | HSD17B10 (0.50) | MAPK1TDP1ALDH1A1TSHRHSD17B10 | |
| SCHEMBL10348031 | 0.78 | CYP3A4 (0.46) | HSD17B10CYP3A4NPC1HTT | |
| SCHEMBL2554329 | 0.78 | SLC2A1 (0.43) | ALDH1A1TSHRMEN1NPC1LMNA | |
| SCHEMBL28848175 | 0.77 | MAPK1 (0.41) | MAPK1TDP1ALDH1A1 | |
| SCHEMBL9397354 | 0.77 | TTR (0.48) | TDP1ALDH1A1MEN1NPC1LMNA | |
| SCHEMBL728777 | 0.75 | PYGL (0.44) | MAPK1TDP1AHRTP53PYGL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 633 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117247359-A | Dendrimer-like lipid compound, liposome, lipid complex, lipid nanoparticle and application thereof | 中国科学院广州生物医药与健康研究院 | 2023-12-19 | — | — | CN | claimed |
| WO-2023236824-A1 | DENDRON-LIKE LIPID COMPOUND, LIPOSOME, LIPID COMPLEX, AND LIPID NANOPARTICLE AND USE THEREOF | 中国科学院广州生物医药与健康研究院 | 2023-12-14 | — | — | WO | claimed |
| US-RE48335-E1 | Polymyxin derivatives as antimicrobial compounds | MONASH UNIVERSITY (AU) | 2020-12-01 | — | — | US | claimed |
| CN-106414480-B | Polymyxin derivatives as antimicrobial compounds | 莫纳什大学 | 2020-08-04 | — | — | CN | claimed |
| US-20170137469-A1 | POLYMYXIN DERIVATIVES AS ANTIMICROBIAL COMPOUNDS | MONASH UNIVERSITY (AU) | 2017-05-18 | — | — | US | claimed |
| EP-3126376-A1 | POLYMYXIN DERIVATIVES AS ANTIMICROBIAL COMPOUNDS | Monash University (AU) | 2017-02-08 | — | — | EP | claimed |
| US-9234087-B2 | Preparation for initiating radical reactions | UNITED INITIATORS GMBH & CO. KG (DE) | 2016-01-12 | — | — | US | claimed |
| WO-2015149131-A1 | POLYMYXIN DERIVATIVES AS ANTIMICROBIAL COMPOUNDS | MONASH UNIVERSITY (AU) | 2015-10-08 | — | — | WO | claimed |
| EP-2288652-B1 | PREPARATION FOR INITIATING RADICAL REACTIONS | UNITED INITIATORS GMBH & CO KG (DE) | 2012-09-19 | — | — | EP | claimed |
| EP-2130858-B1 | Preparations to initiate radical reactions | UNITED INITIATORS GMBH & CO KG (DE) | 2012-07-25 | — | — | EP | claimed |
| EP-0354444-B1 | PROCESS FOR THE INTRODUCTION OF FLUORINE ON AROMATIC NUCLEUS BY NUCLEOPHILIC EXCHANGE | BAYER AG (DE) | 1993-01-20 | — | — | EP | claimed |
| EP-0520336-A2 | Aldehyde derivatives and their use as calpain inhibitors | FUJIREBIO Inc. (JP) | 1992-12-30 | — | — | EP | claimed |
| US-5130474-A | For treatment of gastrointestinal disorders such as colitis, pancreatitis, antispastic agents and biliary diskinesia | ROTTA RESEARCH LABORATORIUM SPA (IT) | 1992-07-14 | — | — | US | claimed |
| EP-0439321-A2 | Thiazolidine derivatives having anti-hypertensive activity and their therapeutic use | Sankyo Company Limited (JP) | 1991-07-31 | — | — | EP | claimed |
| EP-0344184-A1 | DERIVATIVES OF (R) 5-PENTYLAMINO-5-OXOPENTANOIC ACID WITH ANTICHOLECYSTOKININ ACTIVITY. | ROTTA RESEARCH LAB (IT) | 1989-12-06 | — | — | EP | claimed |
| US-4868241-A | POLYVINYL ALCOHOL MODIFIED WITH BENZOIC ACID DERIVATIVE | AMERICAN CYANAMID COMPANY (US) | 1989-09-19 | — | — | US | claimed |
| WO-1988005774-A1 | DERIVATIVES OF (R) 5-PENTYLAMINO-5-OXOPENTANOIC ACID WITH ANTICHOLECYSTOKININ ACTIVITY | ROTTA RESEARCH LABORATORIUM S.P.A. (IT) | 1988-08-11 | — | — | WO | claimed |
| EP-0231922-A2 | Electron beam and X-ray resists | AMERICAN CYANAMID COMPANY (US) | 1987-08-12 | — | — | EP | claimed |
| EP-0057844-B1 | PROCESS FOR THE PREPARATION OF POLYCHLOROBENZOYL CHLORIDES | BAYER AG (DE) | 1983-12-28 | — | — | EP | claimed |
| US-3965107-A | Isothiazolopyridinones | ROHM AND HAAS COMPANY (US) | 1976-06-22 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170137469-A1 | POLYMYXIN DERIVATIVES AS ANTIMICROBIAL COMPOUNDS | VIP, PEPD, NRDC | MAPK1 1345/4885TDP1 4681/4885AHR 3632/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.